RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Niederst, Matthew J

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. [electronic resource] - Nature communications Mar 2015 - 6377 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

2041-1723

10.1038/ncomms7377 doi


Adenocarcinoma--drug therapy
Adenocarcinoma of Lung
Afatinib
Aniline Compounds--pharmacology
Antineoplastic Agents--pharmacology
Carcinoma, Non-Small-Cell Lung--drug therapy
Cell Line, Tumor
Disease Progression
Drug Resistance, Neoplasm--drug effects
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride--pharmacology
Gefitinib
Gene Expression Regulation, Neoplastic
Humans
Lung--drug effects
Lung Neoplasms--drug therapy
Mutation
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins c-bcl-2--genetics
Quinazolines--pharmacology
Recurrence
Retinoblastoma Protein--deficiency
Signal Transduction
Small Cell Lung Carcinoma--drug therapy
Sulfonamides--pharmacology
bcl-X Protein--genetics